Genmab — Marts 2017
-
NKTCL. Se vedlagte link som en genopfrisker på daratumumabs fantastiske muligheder på virkning i NKTCL http://www.nejm.org/doi/full/10.1056/NEJMc1605684#t=article
-
Udgangspuntet var: Due to relatively high expression of the complement inhibitors and lower CD38 expression levels compared to MM cells, daratumumab failed to effectively induce CDC in most patient‐derived NHL and CLL cells 133, 134. Nevertheless, daratumumab and isatuximab showed a marked anti‐tumor activity in mouse xenograft models of NHL in vivo 63, 64, 134. Based on these results, daratumumab is being evaluated in a phase 2 clinical trial in patients with CD38‐positive mantle cell lymphoma,
-
-
Skal man købe i dag, eller falder de, de næste par dage? (ved godt i ikke er spåkoner
) -
Nordea: We shave 2% from ou
r DCF-based target price
to DKK 1,570 (1,595) and we would recommend aggressively
adding to positions if the stock takes a hit of
more than 3-4%. We reiterate our Buy rating on Genmab.
This news prompts us to shave just
2% from our DCF-based target
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind